NanoRepro AG (FRA:NN6) Short-term investments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NN6 NanoRepro AG FRA:NN6
68 GF Score
Price €1.64
GF Value €1.06
! 3 Warning Signs
View Full Analysis

What is NanoRepro AG Short-term investments?

Short-term investments only applies to insurance companies.

FRA:NN6
68GF Score
NanoRepro AG FRA:NN6
Short-term investments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NanoRepro AG (FRA:NN6) Overvalued in 2026?

Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued. The current stock price of €1.64 is trading 54.7% above its estimated GF Value™ of €1.06.

Key valuation signals for FRA:NN6:

  • Short-term investments:
  • GF Value™: €1.06 vs. price of €1.64 (54.7% above fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the FRA:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NanoRepro AG Business Description

Other Exchanges NN6:Germany
Address Untergasse 8, Marburg, DEU, 35037
NanoRepro AG is a German diagnostics and consumer health company that develops, manufactures, and distributes rapid diagnostic tests and dietary supplements. Its product range includes CE-certified self-tests for home use, covering areas such as fertility and pregnancy, sexually transmitted infections, and other health conditions, alongside a portfolio of food supplements marketed under its own brands. The company sells primarily through pharmacies, drugstores, and online channels in Germany and other European markets, targeting both consumers and healthcare professionals. Revenue is generated mainly from sales of its test kits and supplement products, with distribution handled through retail partners and e-commerce platforms. NanoRepro also offers contract manufacturing and private-label services for third parties. The company is headquartered in Marburg, Germany, and its shares are listed on the Frankfurt Stock Exchange.
68GF Score

Get the complete analysis for FRA:NN6

Short-term investments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.64
Price
€1.06
GF Value